Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

Regulatory agencies currently recommend itraconazole (ITZ) as a strong cytochrome P450 3A (CYP3A) inhibitor for clinical drug–drug interaction (DDI) studies. This work by an International Consortium for Innovation and Quality in Pharmaceutical Development working group (WG) is to develop and verify...

Full description

Bibliographic Details
Main Authors: Yuan Chen, Tamara D. Cabalu, Ernesto Callegari, Heidi Einolf, Lichuan Liu, Neil Parrott, Sheila Annie Peters, Edgar Schuck, Pradeep Sharma, Helen Tracey, Vijay V. Upreti, Ming Zheng, Andy Z.X. Zhu, Stephen D. Hall
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12449

Internet

https://doi.org/10.1002/psp4.12449

Similar Items